A5061621194- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Chemical Synthesis and Analysis
- Supramolecular Chemistry and Complexes
- Molecular Sensors and Ion Detection
- Receptor Mechanisms and Signaling
- Cancer-related gene regulation
- Radiopharmaceutical Chemistry and Applications
- Immune Response and Inflammation
- Estrogen and related hormone effects
- Mass Spectrometry Techniques and Applications
- Innovative Microfluidic and Catalytic Techniques Innovation
- Synthesis and Biological Evaluation
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Supramolecular Self-Assembly in Materials
- Advanced Proteomics Techniques and Applications
- Crystallography and molecular interactions
- Click Chemistry and Applications
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Cytokine Signaling Pathways and Interactions
- Cancer Immunotherapy and Biomarkers
Zymeworks (Canada)
2017-2024
University of Victoria
2013-2021
Abstract In recent years, the field of antibody drug conjugates (ADC) has seen a resurgence, largely driven by clinical benefit observed in patients treated with ADCs incorporating camptothecin-based topoisomerase I inhibitor payloads. Herein, we present development novel camptothecin ZD06519 (FD1), which been specifically designed for its application as an ADC payload. A panel analogs different substituents at C-7 and C-10 positions core was prepared tested vitro. Selected compounds...
Abstract Background: HER2-targeted therapies have transformed the treatment of patients with HER2-expressing breast and gastric cancers. Despite this, there remains a need for new treatments that are well tolerated effective not only cancers high HER2 expression levels but also those lower expression. ZW49 is an antibody drug conjugate (ADC) combines novel auristatin payload (potent anti-cancer agent) unique mechanisms action anti-HER2 biparatopic antibody, ZW25, which binds to same domains...
Proteome-wide studies of post-translationally methylated species using mass spectrometry are complicated by high sample diversity, competition for ionization among peptides, and redundancies. Antibody-based enrichment has powered methylation proteomics until now, but the reliability, pan-specificity, polyclonal nature, stability available pan-specific antibodies problematic do not provide a standard, reliable platform investigators. We have invented an anionic supramolecular host that can...
We report a family of highly anionic calixarenes that form discrete homo-dimeric assemblies in pure water, get stronger high salt solutions, and remain assembled complex, denaturing solutions like real urine. The results reveal the potential like-charged subunits for self-assembly high-salt biological fluids.
Meagan A. Beattya, Jil Busmanna, Noah G. Fagena, Graham E. Garnetta & Fraser Hof*aa Department of Chemistry, University Victoria, Canada
<p>Supplementary Figure S2 shows the chemical stability of FD1 (ZD06519)</p>
<p>Supplementary Figure S3 shows the in vitro cytotoxicity assessment of trastuzumab-ADCs both two-dimensional (2D) and three-dimensional (3D) spheroid assays</p>
<p>Synthesis and characterization of free drugs drug-linkers</p>
<p>Supplementary Figure S4 shows the pharmacokinetic analysis of ADCs (total antibody PK) from tolerability study in rats</p>
<p>Supplementary Figure S4 shows the pharmacokinetic analysis of ADCs (total antibody PK) from tolerability study in rats</p>
<p>Synthesis and characterization of free drugs drug-linkers</p>
<p>HPLC-HIC, LC-MS, HPLC-SEC, residual free drug analysis, and endotoxin levels of ADCs</p>
<div>Abstract<p>In recent years, the field of antibody drug conjugates (ADC) has seen a resurgence, largely driven by clinical benefit observed in patients treated with ADCs incorporating camptothecin-based topoisomerase I inhibitor payloads. Herein, we present development novel camptothecin ZD06519 (FD1), which been specifically designed for its application as an ADC payload. A panel analogs different substituents at C-7 and C-10 positions core was prepared tested <i>in...
<p>Supplementary Figure S3 shows the in vitro cytotoxicity assessment of trastuzumab-ADCs both two-dimensional (2D) and three-dimensional (3D) spheroid assays</p>
<p>Supplementary Figure S1 shows the murine plasma stability of T-DL4 and T-DL13</p>
<p>Supplementary Figure S1 shows the murine plasma stability of T-DL4 and T-DL13</p>
<div>Abstract<p>In recent years, the field of antibody drug conjugates (ADC) has seen a resurgence, largely driven by clinical benefit observed in patients treated with ADCs incorporating camptothecin-based topoisomerase I inhibitor payloads. Herein, we present development novel camptothecin ZD06519 (FD1), which been specifically designed for its application as an ADC payload. A panel analogs different substituents at C-7 and C-10 positions core was prepared tested <i>in...